• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

先天性血友病 A 患者的死亡率 - 系统文献回顾。

Mortality in congenital hemophilia A - a systematic literature review.

机构信息

University of Manchester, Manchester, UK.

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

出版信息

J Thromb Haemost. 2021 Jan;19 Suppl 1(Suppl 1):6-20. doi: 10.1111/jth.15189.

DOI:10.1111/jth.15189
PMID:33331043
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7839505/
Abstract

Against a background of a rapidly evolving treatment landscape, a contemporary, evidence-based consolidated understanding of mortality in people with congenital hemophilia A (PwcHA) is lacking. This systematic literature review examines the available data on mortality and causes of death in PwcHA to enable a better understanding of fatalities in PwcHA and evaluate the impact of new treatment paradigms on mortality. A systematic literature review of observational studies was conducted by searching Medline, Embase, and clinical trials registries for articles published from January 2010 to March 2020, using the search terms: hemophilia A (HA), mortality, cause of death. Interventional studies, studies not reporting fatalities, and those reporting only on hemophilia B, acquired HA, or mixed other coagulopathies were excluded. Overall, 7818 unique records were identified and 17 were analyzed. Of these, six reported mortality rates and five reported mortality ratios. Mortality generally decreased over time, despite a spike associated with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection in the 1980s and 1990s. Mortality was strongly correlated with age and hemophilia severity. People with hemophilia had a raised mortality risk compared with the general population, particularly in severe hemophilia, and when infected with HIV or HCV. Causes of death varied across populations, countries, and time in 15 identified studies; however, incomplete and heterogeneous reporting limits evidence. Hemorrhage, HIV, HCV, and hepatic disease were the leading causes of death. A unified approach to reporting mortality and cause of death is needed to understand mortality in PwcHA as treatments continue to advance.

摘要

在治疗领域迅速发展的背景下,目前缺乏对先天性血友病 A 患者(PwcHA)死亡率的现代、基于证据的综合认识。本系统文献回顾检查了 PwcHA 死亡率和死亡原因的现有数据,以便更好地了解 PwcHA 的死亡情况,并评估新治疗模式对死亡率的影响。通过搜索 Medline、Embase 和临床试验登记处,使用“hemophilia A (HA)、mortality、cause of death”等搜索词,对 2010 年 1 月至 2020 年 3 月期间发表的观察性研究进行了系统文献回顾,排除了干预性研究、未报告死亡率的研究以及仅报告血友病 B、获得性血友病或混合其他凝血障碍的研究。总的来说,共确定了 7818 个独特的记录,分析了其中的 17 个。其中,6 个报告了死亡率,5 个报告了死亡率比。尽管在 20 世纪 80 年代和 90 年代与人类免疫缺陷病毒(HIV)/丙型肝炎病毒(HCV)感染相关的死亡率有所上升,但总体上死亡率随着时间的推移而下降。死亡率与年龄和血友病严重程度密切相关。与普通人群相比,血友病患者的死亡率风险更高,尤其是在严重血友病和感染 HIV 或 HCV 的情况下。在 15 项已确定的研究中,不同人群、国家和时间的死亡原因各不相同;然而,不完整和异质的报告限制了证据。出血、HIV、HCV 和肝脏疾病是主要的死亡原因。需要采用统一的方法报告死亡率和死亡原因,以了解随着治疗不断进步,PwcHA 的死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d68/7839505/f572828c5dfd/JTH-19-6-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d68/7839505/7e7d781c1878/JTH-19-6-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d68/7839505/f572828c5dfd/JTH-19-6-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d68/7839505/7e7d781c1878/JTH-19-6-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d68/7839505/f572828c5dfd/JTH-19-6-g002.jpg

相似文献

1
Mortality in congenital hemophilia A - a systematic literature review.先天性血友病 A 患者的死亡率 - 系统文献回顾。
J Thromb Haemost. 2021 Jan;19 Suppl 1(Suppl 1):6-20. doi: 10.1111/jth.15189.
2
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.用于预防既往接受过治疗的 A 型或 B 型血友病患者出血和出血相关并发症的凝血因子浓缩物。
Cochrane Database Syst Rev. 2021 Aug 18;8(8):CD014201. doi: 10.1002/14651858.CD014201.
4
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
5
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
6
Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.职业性HIV暴露后的抗逆转录病毒暴露后预防(PEP)。
Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002835. doi: 10.1002/14651858.CD002835.pub3.
7
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
8
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.成人慢性未抑制的HIV感染中的结构化治疗中断(STI)
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148.
9
Antidepressants for depression in adults with HIV infection.用于感染HIV的成年抑郁症患者的抗抑郁药。
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD008525. doi: 10.1002/14651858.CD008525.pub3.
10
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.

引用本文的文献

1
Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries-Comparisons to Matched Controls.北欧三个国家血友病男性和女性的合并症与死亡率——与匹配对照组的比较
Haemophilia. 2025 May;31(3):401-411. doi: 10.1111/hae.70023. Epub 2025 Mar 18.
2
Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.在3期XTEND-1研究中,使用阿法依那索单抗治疗既往接受过治疗的重度A型血友病患者的出血发作情况。
Am J Hematol. 2025 May;100(5):813-820. doi: 10.1002/ajh.27603. Epub 2025 Feb 10.
3
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection.

本文引用的文献

1
Life expectancy and cause of death in individuals with haemophilia A and B in Norway, 1986-2018.1986-2018 年挪威甲型和乙型血友病患者的预期寿命和死亡原因。
Eur J Haematol. 2020 Nov;105(5):608-615. doi: 10.1111/ejh.13494. Epub 2020 Sep 1.
2
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.直接作用抗病毒治疗在 HIV/HCV 患者中的真实世界疗效。
PLoS One. 2020 Feb 13;15(2):e0228847. doi: 10.1371/journal.pone.0228847. eCollection 2020.
3
Achieving the unimaginable: Health equity in haemophilia.实现难以想象的目标:血友病中的健康公平。
预测 HCV 感染合并血友病患者的肝病结局的因素。
Blood Adv. 2024 Nov 26;8(22):5767-5772. doi: 10.1182/bloodadvances.2024014350.
4
Evaluating Factor VIII Concentrates Using Clot Waveform Analysis.使用凝血波形分析评估凝血因子VIII浓缩物
J Clin Med. 2024 Jun 30;13(13):3857. doi: 10.3390/jcm13133857.
5
Optimizing liver health before and after gene therapy for hemophilia A.优化血友病 A 基因治疗前后的肝脏健康。
Blood Adv. 2024 Oct 8;8(19):5203-5212. doi: 10.1182/bloodadvances.2024013059.
6
Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.艾美赛珠单抗对年龄≥50岁的合并症A型血友病患者有效:4项III期试验分析
Res Pract Thromb Haemost. 2024 Apr 10;8(3):102405. doi: 10.1016/j.rpth.2024.102405. eCollection 2024 Mar.
7
Personalized Prophylaxis with myPKFiT: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients.基于 myPKFiT 的个体化预防治疗:血友病 A 患者真实世界的成本效果分析。
Medicina (Kaunas). 2023 Dec 24;60(1):34. doi: 10.3390/medicina60010034.
8
Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective.用于A型血友病患者的艾美赛珠单抗预防治疗:浪费估计及巴西视角
Saudi Pharm J. 2023 Dec;31(12):101867. doi: 10.1016/j.jsps.2023.101867. Epub 2023 Nov 10.
9
Racial and ethnic differences in reported haemophilia death rates in the United States.美国报告的血友病死亡率中的种族和民族差异。
Haemophilia. 2023 Nov;29(6):1410-1418. doi: 10.1111/hae.14859. Epub 2023 Sep 17.
10
A Qualitative Study Exploring the Experiences and Perceptions of Patients with Hemophilia Regarding Their Health-Related Well-Being, in Salamanca.一项质性研究:探索萨拉曼卡血友病患者对其健康相关福祉的体验与认知
J Clin Med. 2023 Aug 21;12(16):5417. doi: 10.3390/jcm12165417.
Haemophilia. 2020 Jan;26(1):17-24. doi: 10.1111/hae.13862. Epub 2019 Nov 13.
4
Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries.采用国家登记处的荟萃分析方法,确定男性血友病的患病率和出生时患病率。
Ann Intern Med. 2019 Oct 15;171(8):540-546. doi: 10.7326/M19-1208. Epub 2019 Sep 10.
5
Mortality of patients with haemophilia in Brazil: First report.巴西血友病患者死亡率:首次报告。
Haemophilia. 2019 May;25(3):e146-e152. doi: 10.1111/hae.13730. Epub 2019 Mar 15.
6
Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.抗组织因子途径抑制剂 (TFPI) 治疗:血友病治疗的新方法。
Int J Hematol. 2020 Jan;111(1):42-50. doi: 10.1007/s12185-018-2548-6. Epub 2018 Oct 9.
7
Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.影响血友病凝血因子浓缩物质量、安全性和上市批准的因素。
Blood Transfus. 2018 Nov;16(6):525-534. doi: 10.2450/2018.0150-18. Epub 2018 Sep 3.
8
A cross-sectional analysis of cardiovascular disease in the hemophilia population.血友病人群中心血管疾病的横断面分析。
Blood Adv. 2018 Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.
9
Novel approaches to hemophilia therapy: successes and challenges.血友病治疗的新方法:成功与挑战
Blood. 2017 Nov 23;130(21):2251-2256. doi: 10.1182/blood-2017-08-742312. Epub 2017 Oct 10.
10
Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.患有重度甲型或乙型血友病的儿童及青少年的颅内出血——预防性治疗的影响
Br J Haematol. 2017 Oct;179(2):298-307. doi: 10.1111/bjh.14844. Epub 2017 Jul 12.